‘Caution folks’: Top WHO scientist flags ‘dangerous trend’ of mixing Covid-19 vaccines

Geneva, July 12 (ANI): Mixing and matching COVID-19 vaccines from different manufacturers is a “dangerous trend” and could lead to chaos as there is limited data on it on the practice, World Health Organisation (WHO) chief scientist Soumya Swaminathan said on Monday.

Addressing a Covid-19 media briefing, Swaminathan said, “Really want to caution folks, because there is a tendency now for people in countries which enough availability of vaccines to voluntarily start thinking.”

“So it’s a little bit of a dangerous trend here where we’re in a data-free evidence-free zone as far as a mix and match there is limited data on mix and match. There are studies going on, we need to wait for that,” she added.

On the question of booster shots, WHO chief scientist said it will be a chaotic situation in countries if citizens start deciding when they should be taking a second, or a third, or a fourth dose.

“We have four countries that have announced a booster program, and a few more that are thinking about it. If 11 high and upper-middle-income countries decide to some of them are large countries that they will go for a booster for their populations or even subgroups. This will require an additional 800 million doses of vaccine.”

Stressing on the need to prioritise vaccines, Swaminathan said there are still countries where the frontline and health care workers have not been vaccinated and the elderly and the vulnerable.”

The world has so far witnessed over 186 million cases and four million deaths due to the virus, according to the Johns Hopkins University‘s data. (ANI)

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad